Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
15(43%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
8
23%
Ph phase_2
10
29%
Ph phase_1
10
29%
Ph early_phase_1
3
9%
Ph phase_3
2
6%

Phase Distribution

13

Early Stage

10

Mid Stage

2

Late Stage

Phase Distribution33 total trials
Early Phase 1First-in-human
3(9.1%)
Phase 1Safety & dosage
10(30.3%)
Phase 2Efficacy & side effects
10(30.3%)
Phase 3Large-scale testing
2(6.1%)
N/ANon-phased studies
8(24.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

15

trials recruiting

Total Trials

35

all time

Status Distribution
Active(23)
Completed(4)
Terminated(3)
Other(5)

Detailed Status

Recruiting14
Not yet recruiting8
unknown5
Completed4
Withdrawn3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
35
Active
15
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 13 (9.1%)
Phase 110 (30.3%)
Phase 210 (30.3%)
Phase 32 (6.1%)
N/A8 (24.2%)

Trials by Status

unknown514%
active_not_recruiting13%
withdrawn39%
completed411%
not_yet_recruiting823%
recruiting1440%

Recent Activity

Clinical Trials (35)

Showing 20 of 35 trialsScroll for more
NCT07637877Phase 2

Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study

Recruiting
NCT07689058Phase 2

CAR-T in Relapsed/Refractory Multiple Myeloma

Recruiting
NCT07478848Phase 1

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

Recruiting
NCT07223021Phase 3

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Recruiting
NCT03196830Phase 2

CAR-T for R/R B-NHL

Completed
NCT05322330Phase 2

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Completed
NCT07152210Not Applicable

Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer

Withdrawn
NCT07152223Not Applicable

Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

Withdrawn
NCT07152236Not Applicable

Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors

Withdrawn
NCT06504199Phase 2

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

Active Not Recruiting
NCT07169500Phase 1

Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients

Recruiting
NCT07441291Phase 3

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Recruiting
NCT07399769Phase 1

Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors

Recruiting
NCT07370064Phase 1

Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia

Not Yet Recruiting
NCT07338357Early Phase 1

Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML

Not Yet Recruiting
NCT07236203

Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

Recruiting
NCT07143929Phase 1

To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

Recruiting
NCT07070934Phase 2

CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?

Not Yet Recruiting
NCT07070960Not Applicable

A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible

Not Yet Recruiting
NCT06963866Phase 2

Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
35